Literature DB >> 15671746

Hantaviruses: immunology, treatment, and prevention.

Piet Maes1, Jan Clement, Irina Gavrilovskaya, Marc Van Ranst.   

Abstract

Hantaviruses are rodent-borne bunyaviruses that are associated with two main clinical diseases in humans: hemorrhagic fever with renal syndrome and hantavirus pulmonary syndrome. It has been suggested that host-related immune mechanisms rather than direct viral cytopathology may be responsible for the principal abnormality (vascular dysfunction) in these syndromes. This review summarizes the current knowledge on hantaviral host immune responses, immune abnormalities, laboratory diagnosis, and antiviral therapy as well as the current approaches in vaccine development.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15671746     DOI: 10.1089/vim.2004.17.481

Source DB:  PubMed          Journal:  Viral Immunol        ISSN: 0882-8245            Impact factor:   2.257


  59 in total

1.  Genetic reassortment between high-virulent and low-virulent Dobrava-Belgrade virus strains.

Authors:  Sina Kirsanovs; Boris Klempa; Renate Franke; Min-Hi Lee; Günther Schönrich; Andreas Rang; Detlev H Kruger
Journal:  Virus Genes       Date:  2010-08-24       Impact factor: 2.332

2.  Sangassou virus, the first hantavirus isolate from Africa, displays genetic and functional properties distinct from those of other murinae-associated hantaviruses.

Authors:  Boris Klempa; Peter T Witkowski; Elena Popugaeva; Brita Auste; Lamine Koivogui; Elisabeth Fichet-Calvet; Thomas Strecker; Jan Ter Meulen; Detlev H Krüger
Journal:  J Virol       Date:  2012-01-25       Impact factor: 5.103

3.  Characterization of a new Puumala virus genotype associated with hemorrhagic fever with renal syndrome.

Authors:  Udo Bahr; Martin Zeier; Walter Muranyi
Journal:  Virus Genes       Date:  2006-10       Impact factor: 2.332

Review 4.  Treatment of hantavirus pulmonary syndrome.

Authors:  Colleen B Jonsson; Jay Hooper; Gregory Mertz
Journal:  Antiviral Res       Date:  2007-11-21       Impact factor: 5.970

5.  Phase I evaluation of the safety and pharmacokinetics of a single-dose intravenous injection of a murine monoclonal antibody against Hantaan virus in healthy volunteers.

Authors:  Rong Xu; Xiao Yan Yang; Dao Feng Yang; Chang Yong Zou; Pei Li Gong; Fan Dian Zeng
Journal:  Antimicrob Agents Chemother       Date:  2009-09-14       Impact factor: 5.191

6.  Maternally derived recombinant human anti-hantavirus monoclonal antibodies are transferred to mouse offspring during lactation and neutralize virus in vitro.

Authors:  Shuyang Yu; Mifang Liang; Baoliang Fan; Hongtao Xu; Chuan Li; Quanfu Zhang; Dexin Li; Bo Tang; Shijie Li; Yunping Dai; Meili Wang; Min Zheng; Bingxue Yan; Qinghong Zhu; Ning Li
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

7.  'Bedside assessment' of acute hantavirus infections and their possible classification into the spectrum of haemophagocytic syndromes.

Authors:  J Clement; P Colson; V Saegeman; K Lagrou; M Van Ranst
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-04-21       Impact factor: 3.267

8.  The detection of sLFA-3 in plasma of patients with hemorrhagic fever with renal syndrome.

Authors:  Ming Xie; Ping Chen; Lin-Jing He; Bao-Tai Qi; Ping Wang; Xiao-Fang Wang; Hui-Xun Ren
Journal:  Clin Exp Med       Date:  2008-09-27       Impact factor: 3.984

9.  Satellite derived forest phenology and its relation with nephropathia epidemica in Belgium.

Authors:  José Miguel Barrios; Willem W Verstraeten; Piet Maes; Jan Clement; Jean-Marie Aerts; Sara Amirpour Haredasht; Julie Wambacq; Katrien Lagrou; Geneviève Ducoffre; Marc Van Ranst; Daniel Berckmans; Pol Coppin
Journal:  Int J Environ Res Public Health       Date:  2010-06-09       Impact factor: 3.390

10.  Andes virus antigens are shed in urine of patients with acute hantavirus cardiopulmonary syndrome.

Authors:  Paula Godoy; Delphine Marsac; Elias Stefas; Pablo Ferrer; Nicole D Tischler; Karla Pino; Pablo Ramdohr; Pablo Vial; Pablo D T Valenzuela; Marcela Ferrés; Francisco Veas; Marcelo López-Lastra
Journal:  J Virol       Date:  2009-03-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.